Antimicrobial Drug Resistance News Releases

NIH Statement on World Tuberculosis Day, March 24, 2019
March 22, 2019

Tuberculosis (TB) is the world’s leading infectious cause of death. In the 137 years since Dr. Robert Koch’s discovery of Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, as many as one billion people worldwide have died of TB disease. This year’s World TB Day theme is “It’s Time” to end tuberculosis once and for all. We at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, are committed to accelerating the cutting-edge research necessary to ending this ancient disease.

Results of Trial to Stem Hospital-Acquired Bacterial Infections Published
March 5, 2019

New findings from a large, randomized clinical trial that compared two infection control techniques are already being incorporated into practice within the network of U.S. community hospitals where the trial took place. The trial evaluated whether daily bathing with the antiseptic soap chlorhexidine (CHG)—and in those patients with methicillin-resistant Staphylococcus aureus (MRSA), adding the nasal antibiotic mupirocin—more effectively reduced hospital-acquired bacterial infections than bathing with ordinary soap and water.

NIH Study Finds Probiotic Bacillus Eliminates Staphylococcus Bacteria
October 10, 2018

A new study from National Institutes of Health scientists and their Thai colleagues shows that a “good” bacterium commonly found in probiotic digestive supplements helps eliminate Staphylococcus aureus, a type of bacteria that can cause serious antibiotic-resistant infections. The researchers, led by scientists at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), unexpectedly found that Bacillus bacteria prevented S. aureus bacteria from growing in the gut and nose of healthy individuals.

NIAID Releases Strategic Plan to Address Tuberculosis Research
September 26, 2018

WHAT:Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than one billion people—more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

NIH Statement on World Tuberculosis Day, March 24, 2018
March 22, 2018

In the 130 years since the discovery of Mycobacterium tuberculosis (Mtb)—the bacterium that causes tuberculosis (TB)—at least 1 billion people have died from TB. That death toll is greater than the combined number of deaths from malaria, smallpox, HIV/AIDS, cholera, plague and influenza. Today, in commemoration of World TB Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), renews and reinvigorates its commitment to the research needed to end this ancient scourge. 

NIH Scientists Describe Potential Antibody Approach for Treating Multidrug-Resistant Klebsiella pneumoniae
March 13, 2018

Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide, allowing immune system cells called neutrophils to attack and kill the bacteria. The early stage, in vitro research was conducted by scientists at NIAID’s Rocky Mountain Laboratories and the New Jersey Medical School-Rutgers University.

NIH Experts Call for Transformative Research Approach to End Tuberculosis
March 9, 2018

A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in the March 2018 issue of The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Robert W.

U.S. Hospitals Testing Experimental Therapies to Prevent Two Common Bacterial Infections
February 23, 2018

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting U.S. clinical sites participating in two ongoing international Phase 2 clinical trials evaluating investigational antibody-based therapies aimed at preventing potentially antibiotic-resistant infections. By aligning the NIAID Antibacterial Resistance Leadership Group (ARLG) with a large international consortium leading the effort, the U.S. investigators hope to enroll 30 adult patients from 15 intensive care units in the trials.

NIH Study Will Assess Biomarker as Potential Indicator of Whether Lower Respiratory Tract Infections Improve with Antibacterial Treatment
February 13, 2018

A new clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, aims to determine whether low blood levels of the protein procalcitonin can reliably indicate whether a person’s lower respiratory tract infection will improve with antibiotic treatment. 

Common Antimicrobials Help Patients Recover from MRSA Abscesses
June 29, 2017

Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to multiple antibiotics and commonly cause skin infections that can lead to more serious or life-threatening infection in other parts of the body. In new findings published in The New England Journal of Medicine, researchers found that two common, inexpensive antimicrobials can help patients heal from MRSA skin abscesses. The findings suggest that current treatment options for MRSA still have a role, even as scientists continue to search for new antimicrobial products.

NIH-Funded Antibacterial Resistance Leadership Group Details Progress, Challenges
March 9, 2017

In June 2013, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), provided $2 million in funding to establish an Antibacterial Resistance Leadership Group (ARLG) to develop, prioritize and implement a clinical research agenda to address the growing public health threat of antibiotic resistance. A new series of articles appearing in the March 15th issue of the journal Clinical Infectious Diseases details the group’s progress and outlines its ongoing and future efforts.

NIH Scientists Illuminate Role of Staph Toxins in Bacterial Sepsis
February 2, 2017

Staphylococcus epidermidis bacteria are a significant health concern for hospitalized infants, children and anyone with implanted medical devices. The bacteria—typically skin dwellers—can infect the bloodstream and cause a life-threatening condition known as sepsis. Between 1 and 3 million people a year in the United States are diagnosed with sepsis, and between 15 and 30 percent of them die. Severe bacterial sepsis is characterized by an extreme immune response, inflammation, reduced blood flow, clotting, and organ failure. Methicillin-resistant strains of S.

NIH Advances Understanding of Defenses Against Antibiotic-Resistant Klebsiella Bacteria
January 24, 2017

Klebsiella bacteria cause about 10 percent of all hospital-acquired infections in the United States. K. pneumoniae sequence type 258 (ST258) is one of the Carbapenem-Resistant Enterobacteriaceae organisms labeled an urgent threat by the Centers for Disease Control and Prevention. This strain of bacteria is particularly concerning because it is resistant to most antibiotics and kills nearly half of people with bloodstream infections.

Shortened Treatment for Middle Ear Infection is Less Effective than Standard Course
December 21, 2016

A five-day antimicrobial treatment regimen for middle ear infections in young children is inferior to the standard 10-day regimen, according to newly published research in The New England Journal of Medicine (NEJM). Middle ear infections (or “acute otitis media”) are common childhood illnesses often caused by bacteria and usually treated with antibiotics. However, overuse or inappropriate use of antibiotics (for example, to treat viral infections of the middle ear) can accelerate the emergence and spread of antimicrobial resistance.

NIAID-Sponsored Study to Assess Shorter-Duration Antibiotics in Children
November 28, 2016

Physicians at five U.S. medical centers are planning to enroll up to 400 children in a clinical trial to evaluate whether a shorter course of antibiotics—five days instead of 10—is effective at treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of taking antibiotics.

NIH Scientists Detail Pathways for Addressing Antimicrobial Resistance
September 20, 2016

Researchers must address the growing problem of antimicrobial resistance and stay ahead of the inevitable future emergencies of resistant bacteria, according to physicians and scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Writing in JAMA, the authors stress the urgent need for new strategies to identify and develop new antibiotic drug candidates and vaccines and other interventions to prevent bacterial infections.

New NIH Awards Will Support Development of Therapeutic Alternatives to Traditional Antibiotics
January 11, 2016

New NIH awards will support development of therapeutic alternatives to traditional antibiotics the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $5 million in funding for 24 research projects seeking to develop non-traditional therapeutics for bacterial infections to help address the growing health threat of antibiotic resistance.